Trumps new plan for lowering Medicaid drug costs for all 50 states and DC.
- Biden’s plan was about expanding rebate programs and proposing rules to reveal actual drug‑manufacturing costs.
- Trump’s plan goes further — directly tying Medicaid prices to international rates and enforcing supplemental rebates to achieve those prices.
- Biden’s Medicaid drug‑cost plan was proposed but never enacted. Trump’s GENEROUS Model transformed that concept into a nationwide pricing system, delivering projected savings of $64 billion over a decade and lowering costs for millions of Medicaid patients.
- Trump’s plan is operational and producing measurable savings, with early results showing double‑digit price reductions and expanded access. Analysts expect the full impact to be clearer by mid‑2027 once all states finalize rebate cycles.
Trump’s GENEROUS Medicaid Drug‑Cost Plan (2026 – 2031)
Overview: President Trump’s GENEROUS Model (GENErating cost Reductions fOr U.S. Medicaid) is a nationwide initiative to lower prescription‑drug costs for Medicaid patients in all 50 states and D.C.
Launch: January 2026 Administered by: CMS Innovation Center under HHS Secretary Robert F. Kennedy Jr. and CMS Administrator Dr. Mehmet Oz
💊 Key Features
| Element | Description |
|---|---|
| Core Principle | Medicaid pays no more than the lowest price charged in other developed nations (Most‑Favored‑Nation pricing). |
| Participation | All 50 states + D.C. + Puerto Rico applied; 40 states and Puerto Rico have signed formal agreements. |
| Savings Estimate | $64.3 billion over 10 years — $27.6 billion to states and $36.6 billion to the federal government. |
| Drug Scope | Hundreds of brand‑name drugs across major classes (oncology, diabetes, asthma, heart disease). |
| Mechanism | Manufacturers provide supplemental rebates so Medicaid’s net price matches MFN levels; CMS monitors pricing accuracy and shares rebates with states. |
| Duration | Five‑year model (2026 – 2031), voluntary for states and manufacturers. |
🧭 Impact
- Lower drug costs nationwide by aligning U.S. Medicaid prices with international benchmarks.
- Expanded access to lifesaving medicines — early examples include free or deeply discounted Eliquis for heart‑disease patients.
- Budget flexibility for states to reinvest savings in other health or social programs.
- Uniform coverage criteria across participating states, improving predictability for patients and providers.
In summary: Trump’s GENEROUS Medicaid Model brings international‑level drug prices to U.S. Medicaid, covering every state and D.C., with projected savings of $64 billion over a decade and the goal of making essential medicines more affordable for millions of low‑income Americans.
